|
22 Feb 2008 |
Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
|
|
22 Feb 2008 |
Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
|
|
22 Feb 2008 |
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial
|
|
21 Feb 2008 |
Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
|
|
21 Feb 2008 |
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
|
|
20 Feb 2008 |
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
|
|
20 Feb 2008 |
InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast Cancer
|
|
19 Feb 2008 |
Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody Optimization
|
|
18 Feb 2008 |
Takeda Discontinues Development of Matuzumab
|
|
18 Feb 2008 |
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
|
|
14 Feb 2008 |
Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint
|
|
13 Feb 2008 |
YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Caincer
|
|
13 Feb 2008 |
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
|
|
13 Feb 2008 |
Sanofi-aventis enters into Antibody Agreements with Dyaxand "Phage Display Technology"
|
|
12 Feb 2008 |
MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
|
|
12 Feb 2008 |
Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
|
|
11 Feb 2008 |
2008 is a decisive year for the validation of the asthma target interleukin-13
|
|
11 Feb 2008 |
FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
|
|
08 Feb 2008 |
Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
|
|
08 Feb 2008 |
Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
|
|
07 Feb 2008 |
Human Genome Sciences and Xencor Announce Genoma Collaboration
|
|
07 Feb 2008 |
InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin’s Lymphoma With Leading Marketed Product
|
|
07 Feb 2008 |
Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
|
|
06 Feb 2008 |
FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis
|
|
06 Feb 2008 |
OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
|
